These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD. Starr A; Sattler R Brain Res; 2018 Aug; 1693(Pt A):98-108. PubMed ID: 29453960 [TBL] [Abstract][Full Text] [Related]
44. C9orf72 Hexanucleotide Expansions Are Associated with Altered Endoplasmic Reticulum Calcium Homeostasis and Stress Granule Formation in Induced Pluripotent Stem Cell-Derived Neurons from Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Dafinca R; Scaber J; Ababneh N; Lalic T; Weir G; Christian H; Vowles J; Douglas AG; Fletcher-Jones A; Browne C; Nakanishi M; Turner MR; Wade-Martins R; Cowley SA; Talbot K Stem Cells; 2016 Aug; 34(8):2063-78. PubMed ID: 27097283 [TBL] [Abstract][Full Text] [Related]
45. Expression of C9orf72-related dipeptides impairs motor function in a vertebrate model. Swaminathan A; Bouffard M; Liao M; Ryan S; Callister JB; Pickering-Brown SM; Armstrong GAB; Drapeau P Hum Mol Genet; 2018 May; 27(10):1754-1762. PubMed ID: 29528390 [TBL] [Abstract][Full Text] [Related]
46. von Economo Neuron Density and Thalamus Volumes in Behavioral Deficits in Frontotemporal Dementia Cases with and without a C9ORF72 Repeat Expansion. Yang Y; Halliday GM; Hodges JR; Tan RH J Alzheimers Dis; 2017; 58(3):701-709. PubMed ID: 28482638 [TBL] [Abstract][Full Text] [Related]
47. A Chemical Screen Identifies Compounds Limiting the Toxicity of C9ORF72 Dipeptide Repeats. Corman A; Jung B; Häggblad M; Bräutigam L; Lafarga V; Lidemalm L; Hühn D; Carreras-Puigvert J; Fernandez-Capetillo O Cell Chem Biol; 2019 Feb; 26(2):235-243.e5. PubMed ID: 30527999 [TBL] [Abstract][Full Text] [Related]
48. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Simón-Sánchez J; Dopper EG; Cohn-Hokke PE; Hukema RK; Nicolaou N; Seelaar H; de Graaf JR; de Koning I; van Schoor NM; Deeg DJ; Smits M; Raaphorst J; van den Berg LH; Schelhaas HJ; De Die-Smulders CE; Majoor-Krakauer D; Rozemuller AJ; Willemsen R; Pijnenburg YA; Heutink P; van Swieten JC Brain; 2012 Mar; 135(Pt 3):723-35. PubMed ID: 22300876 [TBL] [Abstract][Full Text] [Related]
49. UBQLN2-HSP70 axis reduces poly-Gly-Ala aggregates and alleviates behavioral defects in the C9ORF72 animal model. Zhang K; Wang A; Zhong K; Qi S; Wei C; Shu X; Tu WY; Xu W; Xia C; Xiao Y; Chen A; Bai L; Zhang J; Luo B; Wang W; Shen C Neuron; 2021 Jun; 109(12):1949-1962.e6. PubMed ID: 33991504 [TBL] [Abstract][Full Text] [Related]
50. Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Chew J; Cook C; Gendron TF; Jansen-West K; Del Rosso G; Daughrity LM; Castanedes-Casey M; Kurti A; Stankowski JN; Disney MD; Rothstein JD; Dickson DW; Fryer JD; Zhang YJ; Petrucelli L Mol Neurodegener; 2019 Feb; 14(1):9. PubMed ID: 30767771 [TBL] [Abstract][Full Text] [Related]
51. Reduced autophagy upon C9ORF72 loss synergizes with dipeptide repeat protein toxicity in G4C2 repeat expansion disorders. Boivin M; Pfister V; Gaucherot A; Ruffenach F; Negroni L; Sellier C; Charlet-Berguerand N EMBO J; 2020 Feb; 39(4):e100574. PubMed ID: 31930538 [TBL] [Abstract][Full Text] [Related]
52. An amyloid-like cascade hypothesis for C9orf72 ALS/FTD. Edbauer D; Haass C Curr Opin Neurobiol; 2016 Feb; 36():99-106. PubMed ID: 26555807 [TBL] [Abstract][Full Text] [Related]